Oncoinvent publishes investor presentation on Radspherin alpha therapy for peritoneal metastases

Reuters2026/08/19 08:26

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Oncoinvent highlighted early clinical signals for Radspherin, a single-dose intraperitoneal alpha therapy using radium-224 on CaCO3 microparticles.
Phase 1 ovarian cohort at 7 MBq showed 10% peritoneal recurrence at 24 months; overall recurrence rate 30%.
Phase 1/2a colorectal cohort at 7 MBq showed 28% peritoneal recurrence at 18 months versus about 50% in a literature benchmark.
Safety update showed no dose-limiting toxicity across 68 patients; three serious adverse events were deemed possibly related.
Development plan targets a submission in 2030; ovarian cancer positioned as lead indication with additional peritoneal-metastasis opportunities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncoinvent ASA published the original content used to generate this news brief on August 19, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Oncoinvent publishes investor presentation on Radspherin alpha therapy for peritoneal metastases

You may also like

Crypto prices